Medications

FDA: Zofran 32-mg dose pulled from market

(HealthDay)—The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according to a Drug Safety ...

Medical research

Team finds gene therapy a promising tool for cardiac regeneration

After a heart attack, there is often permanent damage to a portion of the heart. This happens, in part, because cardiac muscle cells are terminally differentiated and cannot proliferate after blood flow is blocked off to ...

page 4 from 9